Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.
The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
- ^ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
- ^ Adis insight: Ecromeximab